software-for-predicting-biologic-drug-viscosity
Viscosity issues often derail promising biologic drug candidates, causing costly late-stage delays and hindering subcutaneous formulations. Learn how predictive software can identify these challenges early, saving time and resources.
Menu
Taming the Syrup: A Clearer Path for Predicting Biologic Drug Viscosity
FAQ
1. Current Situation
2. Typical Market Trends
3. Current Challenges and How They Are Solved
4. How Leukocare Can Support These Challenges
5. Value Provided to Customers
Taming the Syrup: A Clearer Path for Predicting Biologic Drug Viscosity
For Directors in CMC and Drug Product Development, getting a promising biologic to the clinic is a familiar race against time and resources. One of the most persistent hurdles in this race is viscosity. As we push for higher concentrations to make subcutaneous injections possible, many promising molecules become too thick to manufacture or administer. This challenge often appears late in development, causing costly delays or forcing teams back to the drawing board.
1. Current Situation
The move away from intravenous (IV) infusions toward subcutaneous (SC) injections is a major win for patients. It offers the convenience of self-administration at home, reduces the burden on healthcare systems, and improves patient adherence to treatment. [1, 6] This shift puts immense pressure on formulation teams. To deliver a therapeutic dose in a small volume (typically under 2 mL), protein concentrations often need to exceed 100 mg/mL. [1, 3, 6]
At these high concentrations, many monoclonal antibodies (mAbs) and other biologics exhibit a sharp, nonlinear increase in viscosity. [4] A solution that flows easily at low concentrations can turn into something resembling honey, making it difficult to process, filter, and inject through a fine-gauge needle without applying extreme force. [2, 5] This can compromise the drug’s stability, strain manufacturing equipment, and make injections painful for patients. [1, 6] The problem is, we often don't discover these viscosity issues until late-stage development when large amounts of expensive drug substance are finally available for testing.
2. Typical Market Trends
To get ahead of these late-stage surprises, the biopharmaceutical industry is moving toward predictive tools and data-driven development. [7] Companies are increasingly adopting artificial intelligence (AI) and machine learning (ML) to de-risk development and make better go/no-go decisions earlier. [8, 9, 10] More than 90% of drug candidates fail during clinical trials, and predictive modeling offers a way to identify potential liabilities, like high viscosity, long before a molecule enters the clinic. [9, 10]
This trend is driven by the need for speed and efficiency. [8] Fast-track programs and intense competition mean there is no room for multi-year delays caused by unforeseen formulation problems. Teams are looking for ways to build a robust CMC story from the very beginning, making sure a chosen candidate is not just clinically effective but also manufacturable and deliverable.
3. Current Challenges and How They Are Solved
The core challenge in predicting viscosity is that it's a complex, multi-factor problem. [10] It's influenced by a molecule's specific amino acid sequence, its 3D structure, and how it interacts with itself and various formulation excipients.
Traditionally, addressing viscosity has been a trial-and-error process: [11]
Experimental Screening: This involves producing small amounts of many different candidates or formulations and physically measuring their viscosity.
Dilute Solution Measurements: Some methods use measurements from low-concentration solutions to extrapolate high-concentration behavior. [13] While helpful, these predictions can be unreliable because the protein-protein interactions that drive high viscosity are fundamentally different in crowded, high-concentration environments. [7]
In recent years, in silico or computational models have emerged as a promising alternative. [7] Early models relied on a few molecular descriptors, like surface charge or hydrophobicity, to make predictions. While a step forward, their accuracy has been limited. [14, 15] More advanced ML models are now being trained on larger datasets to better predict viscosity from a protein's sequence alone. But many of these tools remain academic or are built on limited internal data, restricting how broadly they can be used. A reliable predictive tool that can guide formulation strategy is still needed. [14, 15]
4. How Leukocare Can Support These Challenges
This is where a focused, data-driven approach to formulation can make a difference. [11] At Leukocare, we combine AI-powered predictive modeling with deep formulation science to address viscosity challenges head-on. Our approach isn't just about running a sequence through a piece of software; it's a collaborative process designed to give you a clear path forward.
Our platform analyzes the unique structural and physicochemical properties of your molecule to predict its behavior in a high-concentration setting. This isn't a black box. [17, 18] The AI gives us a data-driven hypothesis, narrowing hundreds of potential formulation conditions to a small, manageable set. Our formulation scientists then use this strategic map to design targeted, high-value experiments. [18]
This combination of predictive analytics and expert lab work allows us to:
Identify viscosity risks very early in development.
Systematically screen excipients that can mitigate those risks.
Find the right formulation faster, using significantly less material.
We act as a strategic partner, helping you build a robust formulation that is not just stable but also optimized for manufacturing and delivery. [18]
5. Value Provided to Customers
For a Director of CMC or Drug Product Development, the value of this approach is measured in reduced risk and accelerated timelines.
Speed to Clinic: By identifying and solving viscosity problems early, we help you avoid the delays that can derail a program. You get to a stable, injectable formulation faster.
Material Savings: Our predictive method allows us to design smaller, more informative experiments. This can cut material requirements by 50-70% compared to traditional high-throughput screening, preserving your valuable drug substance for other critical studies.
Increased Confidence: Our data-driven process provides a strong, logical foundation for your formulation strategy. This builds a robust CMC story that gives you, your investors, and regulatory agencies confidence in your product. [18]
A Strategic Co-pilot: We don't just execute; we partner with your team. We provide the specialized knowledge and predictive tools to support your internal experts, helping them make informed decisions without adding overhead.
By turning formulation development from a guessing game into a predictive science, we help ensure your most promising molecules have the best possible chance of reaching patients.
FAQ
Q1: How accurate are AI-guided viscosity predictions?
A: The accuracy of predictive models has improved significantly with the use of deep learning and larger datasets. Some models report accuracy rates of over 80-90% in correctly classifying high- and low-viscosity candidates. Our approach uses AI to generate a strong starting hypothesis, which is then confirmed and refined with targeted, efficient laboratory experiments to ensure the final formulation is robust. [14, 15]
Q2: How much material is needed for an initial assessment?
A: A key benefit of a predictive approach is the significant reduction in material needed. While traditional screening can require many grams of a drug substance, our AI-guided process allows us to gain critical insights with much smaller amounts, often reducing material needs by more than half. [18] This is especially valuable in the early stages of development when material is scarce.
Q3: Can these predictive models handle new or complex modalities like bispecific antibodies?
A: Yes. Modern AI models are designed to learn from a molecule's fundamental physicochemical properties. [18] Instead of just comparing a new molecule to past projects, our platform analyzes its specific sequence and predicted structure. This allows us to adapt our models to the unique stability and viscosity challenges presented by novel formats, including bispecifics, antibody-drug conjugates, and viral vectors.
Q4: Does this approach work for biologics that are already in later-stage development?
A: Absolutely. [18] While it's ideal to address viscosity risks early, our platform can also be used to troubleshoot and optimize formulations for later-stage candidates. If you encounter unexpected viscosity problems, we can analyze your molecule and current formulation to identify the root cause and develop a targeted strategy to fix it, potentially salvaging an otherwise promising candidate.
